Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D H Johnson

Showing results (331-340 of 376) with videos related to

Pageof 38
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2012
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancerJ-C Soria, A Mauguen, M Reck, et al.
Oncogene|April 13, 2010
Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediatorsS E Wang, Y Yu, T L Criswell, et al.
International Journal of Radiation Oncology, Biology, Physics|June 23, 2000
A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study)H Choy, R F Devore, K R Hande, et al.
The Annals of Thoracic Surgery|December 1, 1984
The feasibility of adjuvant surgery in limited-stage small cell carcinoma: a prospective evaluationR L Prager, J M Foster, J D Hainsworth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamideM P Goren, L B Anthony, K R Hande, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1993
Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high-dose-intensity combination chemotherapyT M Waits, F A Greco, J P Greer, et al.
Investigational New Drugs|April 9, 2001
A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignanciesC D Blanke, M Stipanov, J Morrow, et al.
Ophthalmology|November 18, 1998
The probability of blindness from open-angle glaucomaM G Hattenhauer, D H Johnson, H H Ing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering resultsO S Breathnach, B Freidlin, B Conley, et al.
Clinical Lung Cancer|January 22, 2004
Docetaxel and cisplatin in patients with advanced non small-cell lung cancer (NSCLC): a multicenter phase II trialC P Belani, P Bonomi, T W Dobbs, et al.
Pageof 38

Showing results (331-340 of 376) with videos related to

Sort By:
Pageof 38
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2012
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancerJ-C Soria, A Mauguen, M Reck, et al.
Oncogene|April 13, 2010
Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediatorsS E Wang, Y Yu, T L Criswell, et al.
International Journal of Radiation Oncology, Biology, Physics|June 23, 2000
A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study)H Choy, R F Devore, K R Hande, et al.
The Annals of Thoracic Surgery|December 1, 1984
The feasibility of adjuvant surgery in limited-stage small cell carcinoma: a prospective evaluationR L Prager, J M Foster, J D Hainsworth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamideM P Goren, L B Anthony, K R Hande, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1993
Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high-dose-intensity combination chemotherapyT M Waits, F A Greco, J P Greer, et al.
Investigational New Drugs|April 9, 2001
A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignanciesC D Blanke, M Stipanov, J Morrow, et al.
Ophthalmology|November 18, 1998
The probability of blindness from open-angle glaucomaM G Hattenhauer, D H Johnson, H H Ing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering resultsO S Breathnach, B Freidlin, B Conley, et al.
Clinical Lung Cancer|January 22, 2004
Docetaxel and cisplatin in patients with advanced non small-cell lung cancer (NSCLC): a multicenter phase II trialC P Belani, P Bonomi, T W Dobbs, et al.
Pageof 38